AL Amyloidosis
Oncology·MeSH: Immunoglobulin Light-chain Amyloidosis
Prevalence
5.0 / 100K
5 drugs in development·4 companies·8 clinical trials
Drug Pipeline by Phase
Phase 3(2)
Phase 1(1)
| Drug | Company |
|---|---|
| Isatuximab | Merus N.V. (MRUS) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| azd0120 | ALEXION PHARMACEUTICALS, INC. (ALXN) |
Phase 4(1)
| Drug | Company |
|---|---|
| Isatuximab | Filana Therapeutics Inc. (FLNA) |
Compare drugs
Frequently asked questions
How many drugs are in development for AL Amyloidosis?
BioSniper tracks 5 drugs in development for AL Amyloidosis across 4 companies.
How many clinical trials target AL Amyloidosis?
There are 8 clinical trials targeting AL Amyloidosis tracked by BioSniper.
What is the prevalence of AL Amyloidosis?
The estimated prevalence of AL Amyloidosis is approximately 5.0 per 100,000 population.
Deep-dive into AL Amyloidosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis